Here's one reason why experts think the CSL share price can rise 65%!

There's more than one reason why experts are excited by the potential of CSL.

The CSL Ltd (ASX: CSL) share price has taken a dive over the last several months. As the chart below shows, it has fallen almost 50% from August 2025. But, experts think there's a chance that the ASX healthcare share could recover a lot of the lost ground.

The global biotech business provides a number of healthcare products, including blood plasma-related treatments and vaccines.

UBS recently released a note that outlined one of the reasons why investors can be excited by the business.

Cropped shot of a young female scientist working on her computer in the laboratory.

Image source: Getty Images

UBS is positive on the biotech giant

The broker said that there has been a rapid uptake of CSL's Andembry since the launch in mid-2025, with more than 1,000 patients on the therapy. UBS estimates this is around 15% of patients on prophylactic treatment across the major markets where it has been approved.

At a US price of around $400,000, the broker said this early momentum should underpin "strong second-half FY26 sales and extend into FY27".

UBS suggests that its hereditary angioedema (HAE) forecasts may prove conservative, as it has allowed for competitive pressure in its projections and therefore expects CSL's HAE market share to peak in FY27.

The broker is projecting that CSL's market share could rise from around 20% in FY25 to a peak of 27% in FY27. UBS said its cautious stance reflects "gradual switching from incumbent therapies, including Haegarda, and competition from other new therapies, both approved and currently in clinical trials."

UBS believes there's "meaningful upside if Andembry takes more" market share.

The broker said its scenario analysis suggests the FY30 (estimated) earnings could get a 9% potential boost if CSL lifts its market share to 40% of the global HAE market. While ambitious, UBS said that possible outcome is "credible given Andembry's clear advantages in convenience and patient experience".

UBS also noted that CSL's long history with this patient group positions it well to take share from the market leader, Takeda.

Is the CSL share price a buy?

The broker is still bullish on the business, despite the market's pessimism.

UBS currently has a buy rating on the business, with a price target of $235. A price target tells investors where they think the share price will be in a year from the time of the investment call. The broker's price target suggests a possible rise of 66% over the next year.

The broker projects that the business could generate net profit of US$3.4 billion in FY26.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »